These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 15823280)

  • 41. A xanthomatosis-susceptibility gene may exist in a Syrian family with familial hypercholesterolemia.
    Vergopoulos A; Bajari T; Jouma M; Knoblauch H; Aydin A; Bähring S; Mueller-Myhsok B; Dresel A; Joubran R; Luft FC; Schuster H
    Eur J Hum Genet; 1997; 5(5):315-23. PubMed ID: 9412789
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Assessment of carotid atherosclerosis in normocholesterolemic individuals with proven mutations in the low-density lipoprotein receptor or apolipoprotein B genes.
    Huijgen R; Vissers MN; Kindt I; Trip MD; de Groot E; Kastelein JJ; Hutten BA
    Circ Cardiovasc Genet; 2011 Aug; 4(4):413-7. PubMed ID: 21642693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular disease in familial hypercholesterolaemia: influence of low-density lipoprotein receptor mutation type and classic risk factors.
    Alonso R; Mata N; Castillo S; Fuentes F; Saenz P; Muñiz O; Galiana J; Figueras R; Diaz JL; Gomez-Enterría P; Mauri M; Piedecausa M; Irigoyen L; Aguado R; Mata P;
    Atherosclerosis; 2008 Oct; 200(2):315-21. PubMed ID: 18243212
    [TBL] [Abstract][Full Text] [Related]  

  • 44. LDL receptor mutation genotype and vascular disease phenotype in heterozygous familial hypercholesterolaemia.
    Brorholt-Petersen JU; Jensen HK; Jensen JM; Refsgaard J; Christiansen T; Hansen LB; Gregersen N; Faergeman O
    Clin Genet; 2002 Jun; 61(6):408-15. PubMed ID: 12121347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia.
    Vohl MC; Gaudet D; Moorjani S; Tremblay G; Perron P; Gagné C; Lesiège D; Bergeron J; Lupien PJ; Després JP
    Eur J Clin Invest; 1997 May; 27(5):366-73. PubMed ID: 9179542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.
    Bertolini S; Cantafora A; Averna M; Cortese C; Motti C; Martini S; Pes G; Postiglione A; Stefanutti C; Blotta I; Pisciotta L; Rolleri M; Langheim S; Ghisellini M; Rabbone I; Calandra S
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):E41-52. PubMed ID: 10978268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical studies in a kindred with a kinetic LDL receptor mutation causing familial hypercholesterolemia.
    Bilheimer DW; East C; Grundy SM; Nora JJ
    Am J Med Genet; 1985 Nov; 22(3):593-8. PubMed ID: 4061492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipoprotein profile assessed by 2D-1H-NMR and subclinical atherosclerosis in children with familial hypercholesterolaemia.
    Rodríguez-Borjabad C; Ibarretxe D; Girona J; Ferré R; Feliu A; Amigó N; Guijarro E; Masana L; Plana N;
    Atherosclerosis; 2018 Mar; 270():117-122. PubMed ID: 29407879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. FH-Freiburg: a novel missense mutation (C317Y) in growth factor repeat A of the low density lipoprotein receptor gene in a German patient with homozygous familial hypercholesterolemia.
    Nauck MS; Scharnagl H; Nissen H; Schürmann C; Matern D; Nauck MA; Wieland H; März W
    Atherosclerosis; 2000 Aug; 151(2):525-34. PubMed ID: 10924730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
    Drogari E; Ragia G; Mollaki V; Elens L; Van Schaik RH; Manolopoulos VG
    Pharmacogenomics; 2014 Dec; 15(16):1963-72. PubMed ID: 25521355
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detecting familial hypercholesterolemia earlier in life by actively searching for affected children:The DECOPIN project.
    Ibarretxe D; Rodríguez-Borjabad C; Feliu A; Bilbao JÁ; Masana L; Plana N
    Atherosclerosis; 2018 Nov; 278():210-216. PubMed ID: 30312929
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway.
    Tonstad S; Leren TP; Sivertsen M; Ose L
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1009-14. PubMed ID: 7627689
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of mildly oxidized low-density lipoprotein (electronegative LDL) and its auto-antibodies IgG in children and adolescents hypercholesterolemic offsprings.
    Barros MR; Bertolami MC; Abdalla DS; Ferreira WP
    Atherosclerosis; 2006 Jan; 184(1):103-7. PubMed ID: 15899483
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cascade screening of familial hypercholesterolemia must go on.
    Galema-Boers JM; Versmissen J; Roeters van Lennep HW; Dusault-Wijkstra JE; Williams M; Roeters van Lennep JE
    Atherosclerosis; 2015 Oct; 242(2):415-7. PubMed ID: 26282946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Genotypic and phenotypic variation in familial hypercholesterolemia.
    Thompson GR; Seed M; Niththyananthan S; McCarthy S; Thorogood M
    Arteriosclerosis; 1989; 9(1 Suppl):I75-80. PubMed ID: 2912434
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ABO blood group is a cardiovascular risk factor in patients with familial hypercholesterolemia.
    Paquette M; Dufour R; Baass A
    J Clin Lipidol; 2018; 12(2):383-389.e1. PubMed ID: 29290540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background.
    Choumerianou DM; Dedoussis GV
    Clin Chem Lab Med; 2005; 43(8):793-801. PubMed ID: 16201887
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increased carotid artery intima-media thickness is associated with a novel mutation of low-density lipoprotein receptor independently of major cardiovascular risk factors.
    Pauciullo P; Giannino A; De Michele M; Gentile M; Liguori R; Argiriou A; Carlotto A; Faccenda F; Mancini M; Bond MG; De Simone V; Rubba P
    Metabolism; 2003 Nov; 52(11):1433-8. PubMed ID: 14624402
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Familial hypercholesterolemia mutations in the Middle Eastern and North African region: a need for a national registry.
    Bamimore MA; Zaid A; Banerjee Y; Al-Sarraf A; Abifadel M; Seidah NG; Al-Waili K; Al-Rasadi K; Awan Z
    J Clin Lipidol; 2015; 9(2):187-94. PubMed ID: 25911074
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation.
    Scicali R; Di Pino A; Pavanello C; Ossoli A; Strazzella A; Alberti A; Di Mauro S; Scamporrino A; Urbano F; Filippello A; Piro S; Rabuazzo AM; Calabresi L; Purrello F
    Sci Rep; 2019 Dec; 9(1):20354. PubMed ID: 31889114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.